BMO Capital reiterates a Buy rating on Chemours with a $26 target, citing 32% upside from current levels amid sector adjustments.
BMO Capital analyst John McNulty maintained a Buy rating on Chemours (CC) with a $26 price target, aligning with the median Wall Street target of $25. The stock trades 11% below the lowest analyst target of $21, signaling potential upside.
Mizuho Securities recently cut its price target for Chemours from $30 to $25 but retained an Outperform rating, reflecting a 32% upside. The firm adjusted its outlook for basic chemical producers due to lower oil prices, which reduced expected cost advantages for natural gas-based production.
Chemours operates in titanium technologies, thermal solutions, and advanced performance materials, with demand for tech materials expected to benefit from long-term investments in computing infrastructure.